ALK and non-small cell lung carcinoma: FISH‐positive/IHC‐negative and FISH‐negative/IHC‐positive cases responding to ALK inhibitors have been reported in NSCLC,32, 33 and two NSCLC patients with <15% fusion cells by FISH but low copy numbers of EML4‐ALK fusion by qPCR responded well to crizotinib after failure of chemotherapy was described.34